NEW YORK, NY / ACCESSWIRE / December 2, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Las Vegas Sands Corp. (NYSE:LVS)

Investors Affected : February 27, 2016 - September 15, 2020

A class action has commenced on behalf of certain shareholders in Las Vegas Sands Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/las-vegas-sands-corp-loss-submission-form/?id=11325&from=1

First American Financial Corp. (NYSE:FAF)

Investors Affected : February 17, 2017 - October 22, 2020

A class action has commenced on behalf of certain shareholders in First American Financial Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/first-american-financial-corp-loss-submission-form/?id=11325&from=1

Zosano Pharma Corporation (NASDAQ:ZSAN)

Investors Affected : February 13, 2017 - September 30, 2020

A class action has commenced on behalf of certain shareholders in Zosano Pharma Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.